Affinity Molecules

Affinity Molecules is a private, revenue-generating biotech services company providing critical R&D and pre-clinical development support to the biologics industry. Its core expertise lies in creating manufacturing-grade CHO cell lines for biologics production, alongside a suite of protein expression, purification, and assay development services. A recent NIH Phase I SBIR grant for a novel mRNA vaccine production platform indicates an expansion into proprietary technology development. The company operates primarily as a CRO/CDMO-like service provider, catering to academic, biotech, and pharmaceutical clients.

Expertise in CHO stable cell line generation for biologics. Developing a proprietary solid-phase enzymatic platform for scalable production of capped, polyadenylated mRNA for vaccines/therapeutics (NIH-funded).

In services, it competes with large CDMOs (Lonza, Catalent) and niche CROs. In mRNA production tech, it would face entrenched methods and well-funded tools companies. Its differentiation is the niche focus on GMP-amenable cell lines and the novel solid-phase mRNA synthesis approach.